A Randomized, Open, Single-dose, 3-treatment, 3-period, 6-sequence Crossover Study in Healthy Male Subjects to Evaluate the Pharmacokinetics of GLA5PR GLARS-NF1 Tablet 150mg and LYRICA® Capsule 75mg
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 主要终点
- AUClast
研究概览
简要总结
The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.
GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech.
GLARS(Geometrically Long Absorption Regulated System) is New Solution to Sustained Absorption by Extending the Absorption Site.
To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".
详细描述
Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.
The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.
As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.
At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.
This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •20~45 years old, Healthy Adult Male Subject
- •17.5~30.5kg/m2(BMI) and ≥ 45kg
排除标准
- •SBP ≥ 140mmHg or DBP ≥ 90mmHg
研究组 & 干预措施
GLA5PR GLARS-NF1 tab.150mg(fasted)
GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
干预措施: Pregabalin 150mg (Drug)
GLA5PR GLARS-NF1 tab.150mg(after high fat meal)
GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
干预措施: Pregabalin 150mg (Drug)
Lyrica Capsule 75mg(after high fat meal)
Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
干预措施: Pregabalin 75mg (Drug)
结局指标
主要结局
AUClast
时间窗: 36hrs
Pharmacokinetic of Pregabalin
Cmax
时间窗: 36hrs
Pharmacokinetic of Pregabalin
次要结局
- Vd/F(36hrs)
- CL/F(36hrs)
- Tmax(36hrs)
- t1/2(36hrs)
- AUCinf(36hrs)
